MedTrace Logo

TDCS and Aphasia Therapy in the Acute Phase After Stroke

NCT03297450 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-09-19

No results posted yet for this study

Summary

This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the acute stage after stroke. Half of the participants will receive aphasia therapy and tDCS, the other half will receive aphasia therapy and sham-tDCS.

Conditions

  • Aphasia Following Cerebral Infarction

Interventions

DEVICE

tDCS

C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA

BEHAVIORAL

Aphasia therapy

Based on linguistic tests, individualized aphasia therapy will be provided

DEVICE

Sham-tDCS

tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Veerle De Herdt, Prof. Dr. · University Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-02
Primary Completion
2018-03-30
Completion
2018-03-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03297450 on ClinicalTrials.gov